Latest Trump executive order threatens broad cut to US drug prices
US President Donald Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services (HHS) and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services (CMS) to lower US drug prices if no deal is reached.
Responding to the development, financial services company Morningstar’s director Karen Anderson explained her views on why this matters.
The President's goal of bringing US drug prices more in line with pricing in other developed countries is among the more feared potential policy changes in the biopharma industry, although we have generally seen sweeping changes as a low-probability scenario.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze